Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $34.36 USD
Change Today +0.13 / 0.38%
Volume 488.7K
ACOR On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

acorda therapeutics inc (ACOR) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/15 - $45.45
52 Week Low
06/2/15 - $28.52
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

acorda therapeutics inc (ACOR) Related Businessweek News

No Related Businessweek News Found

acorda therapeutics inc (ACOR) Details

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes novel therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), a potassium channel blocker to improve walking in patients with multiple sclerosis (MS); Zanaflex Capsules and Zanaflex tablets for the management of spasticity, a symptom of central nervous system disorders; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. The company also markets Ampyra as Fampyra in Europe, Asia, and the Americas. It is also involved in developing CVT-301, which is in Phase III clinical trial for the treatment of OFF episodes in Parkinson’s disease; Dalfampridine that is in Phase III clinical trial for the treatment of chronic post-stroke deficits; Neuregulin Program, which is in Phase Ib clinical trial for the treatment of heart failure; CVT-427 that is in pre-clinical development for the treatment of migraines; Remyelinating Antibodies Program, which is in Phase I clinical trial for the treatment of MS; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury, as well as developing Plumiaz, a proprietary nasal spray formulation of diazepam for the treatment of people with epilepsy. The company has a collaboration agreement with Biogen Idec International GmbH for the development and commercialization of products containing aminopyridines. The company was founded in 1995 and is headquartered in Ardsley, New York.

489 Employees
Last Reported Date: 02/27/15
Founded in 1995

acorda therapeutics inc (ACOR) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $745.8K
Chief Financial Officer
Total Annual Compensation: $428.3K
Chief of Business Operations
Total Annual Compensation: $312.7K
President of International, General Counsel a...
Total Annual Compensation: $555.5K
Chief Medical Officer
Total Annual Compensation: $434.0K
Compensation as of Fiscal Year 2014.

acorda therapeutics inc (ACOR) Key Developments

Acorda Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Sales Guidance for the Year 2015; Provides Cash Flow Guidance for the Year 2015

Acorda Therapeutics, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter the company reported that total revenues were $113,707,000 against $97,129,000 reported last year. Operating income was $5,692,000 against $10,979,000 a year ago period. Income before income taxes was $2,127,000 against $10,718,000 reported last year. Net income was $997,000 or $0.02 per diluted share against net income of $4,685,000 or $0.11 per diluted share reported a year ago. Non-GAAP net income was $13,483,000 or $0.31 per diluted share against $17,737,000 or $0.42 per diluted share reported last year. For the six months, the company reported total revenues of $213,559,000 compared to $177,648,000 reported in the same period a year ago. Operating income was $4,433,000 against $14,396,000 reported last year. Loss before income taxes was $2,997,000 against income before income taxes of $14,215,000 reported a year ago. Net loss was $2,088,000 or $0.05 per diluted share against net income of $5,390,000 or $0.13 per diluted share reported a year ago. Non-GAAP net income was $19,945,000 or $0.46 per diluted share against $26,531,000 or $0.63 per diluted share reported last year. The company narrowed 2015 AMPYRA net sales guidance from $405 million -$420 million to $410 million -$420 million. The Company revised 2015 R&D guidance from $150-$160 million to $140-$150 million. This guidance excludes share-based compensation. The company expects to be cash flow positive in 2015.

Acorda Therapeutics, Inc., Q2 2015 Earnings Call, Jul 30, 2015

Acorda Therapeutics, Inc., Q2 2015 Earnings Call, Jul 30, 2015

Acorda Therapeutics, Inc. Presents Data from a Phase 2b Clinical Trial of CVT-301

Acorda Therapeutics, Inc. presented data from a Phase 2b clinical trial of CVT-301, an inhaled levodopa (L-dopa) under development for the episodic treatment of OFF episodes associated with Parkinson's disease (PD). OFF episodes are characterized by a re-emergence of PD motor symptoms, such as impaired ability to move, muscle stiffness and tremor. The trial showed that patients experiencing an OFF episode, treated with CVT-301, showed significantly greater improvements in motor function than patients treated with inhaled placebo; the difference in improvement was already apparent 10 minutes after dosing and was durable for at least an hour, the longest time point at which patients were measured. The Phase 2b trial was a randomized, double blind, placebo-controlled, multicenter study in 86 people with PD for the treatment of OFF episodes. Participants were randomized to self-administer CVT-301 or placebo as an adjunct to oral PD medications. Participants received 35mg of CVT-301 or placebo delivered to the lung in weeks 1 and 2, and 50mg of drug or placebo delivered to the lung in weeks 3 and 4. In-office assessments of the Unified Parkinson's Disease Rating Scale Part 3 (UPDRS III) were performed at weeks 1, 2 and 4. The primary endpoint was defined as the mean change from baseline in UPDRS III score (10-60 minutes post dose) after 4 weeks of treatment. UPDRS III is an established scale to monitor PD motor impairment, and is considered a standard in the field. In this study, participants receiving CVT-301 showed a statistically significant and clinically important reduction in average UPDRS III motor score compared to placebo and across all measured time points beginning at 10 and up to 60 minutes post administration. Both doses of CVT-301 were well tolerated, with no increase relative to placebo in troublesome or non troublesome dyskinesias during ON periods. There were no serious adverse events reported in the drug group, and the incidence of drug-related adverse events was similar between treatment groups. The most common adverse events were dizziness, headache and cough; there were no adverse events on cardiovascular or lung function. PD patients were able to self-administer treatment while in an OFF state.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACOR:US $34.36 USD +0.13

ACOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $48.81 USD +0.99
Depomed Inc $31.50 USD +0.97
Durect Corp $2.35 USD -0.04
Impax Laboratories Inc $48.46 USD +0.10
Isis Pharmaceuticals Inc $54.93 USD +1.76
View Industry Companies

Industry Analysis


Industry Average

Valuation ACOR Industry Range
Price/Earnings 100.0x
Price/Sales 3.3x
Price/Book 2.6x
Price/Cash Flow 144.2x
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACORDA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at